Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 4, 1994 - Issue 11
Submit an article Journal homepage
12
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Overview Cardiovascular & Renal: Angiotensin antagonists: agents that interact with the AT2 receptor and their potential therapeutic utilities

John C Hodges Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA
Pages 1325-1338 | Published online: 03 Mar 2008

References to Primary Literature

  • BUMPUS FM, CATT KJ, CHIU AT, DE GASPARD M, GOOD-FRIEND T, HUSAIN A, PEACH MJ, TAYLOR DM, TIMMER-MANS PB: Nomenclature for anglotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertens. (1991) 17: 720–721.
  • BeHLMAYER P: Angloten.sin 11 antagonists: patent ac-tivity since the discovery of DuP753. Carr. Opin. 7her. Patents (1992) 2: 1693–1718.
  • DUDLEY DT, HAMBY JM: Recent advances in angiotensin 11 receptor antagonists. Cur. Opin. 7ber. Patents (1993) 3: 581–596.
  • LOGAN RL: Recent advances in the treatment of heart failure: Patent activity in 1992. Carr. Opin. Ther. Patents (1993) 3: 991–1025. Includes a section on ATi selective angiotensin II inhibitors (pp. 1001–1010) that describes many clinical candidates.
  • GREENLEE WJ, MANTLO NB, EDITORS G: Recent advances in the design and synthesis of angiotensin 11 receptorantagonists. Bioorg. Med. Chem. Lett. (1994) 4: 15–222. An excellent collection of manuscripts describing many new ATI antagonists of unknown status with respect to clinical studies.
  • TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF,BENEFIELD P, CARINI DJ, LEE RJ, WEXLER RR, SAYE JAM, SMITH RD: Angiotensin II receptors and angiotensin receptor antagonists. Pharm. Rev. (1993) 45: 205–251. The latest and most exhaustive of several recent reviews on func-tional correlates of angiotensin receptors by these authors.
  • WHITEBREAD S, MELE M, KAMBER B, DE GASPARO M:Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem. Biophys, Res. Commun. (1989) 163: 284291. The first paper describing angiotensin II receptor subtypes.
  • DUDLEY DT, PANEK EL, MAJOR TC, LU GH, BRUNS RF, KLINICEFUS BA, HODGES JC, WEISHAAR RE: Subclasses of angiotensin II binding sites and their functional significance. Mol. Pbarm. (1990) 38: 370377.
  • CHIU AT, HERBLIN WF, MCCALL DE, ARDECKY RJ, CARINI DJ, DUNCIA JV, PEASE LJ, WONG PC, WEXLER RR, JOHNSON AL, 'rIMMERMANS PBMWM: Identification of angiotenshi II receptor subtypes. Biochem. Biophys. Res. Commun. (1989) 165: 196–203.
  • CHANG RSL, LOTTI VJ: Two distinct angiotensin 1:1receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol. Pharmacol. (1990) 29: 347–351.
  • GEHLERT DR, GACKENHEIMER SL, REEL JK, UN HS, STE-INBERG MI: Nonpeptide angiotensin II receptor antago-nists discriminate subtypes of 125I-angiotensin binding sites in the rat brain. Eur. j Pharmacol. (1990) 187: 123–126.
  • SPETH RC, KIM K: Discrimination of two angiotensin 11 receptor subtypes with a selective agonist analogue of angiotensin 11, paminophenylalanine6-angiotenski IL Biochem. Biophys. Res. Commun. (1990) 169.
  • MUKOYAMA M, NAKAJIMA M, HORIUCHI M, SASAMURAH, PRATT RE, DZAU VJ: Expression cloning of type 2angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. (1993) 268: 24539–24542. First report of AT2 receptor cloning from rat foetus.
  • KAMBAYASHI Y, BARDHAN S, TAKAHASHI K, TSUZUKI S,INUI H, HAMAKUBO T, INAGAMI T: Molecular cloningof a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase Inhibition. I. Biol. Chem. (1993) 268: 24543–24546. First report of AT2 receptor cloning from PC12w cells.
  • HODGES JC, HAMBY JM, BLANKLEY g: Angiotensin 11 receptor binding inhibitors. Drugs Fut. (1992) 17: 575593.
  • LEUNG ICH, ROSCOE WA, SMITH RD, TIMMERMANS PB, CHIU AT: Characterization of biochemical responses of angiotensin II (AT2) binding sites in the rat pheochro- mocytoma PC12W cells. Eur. J. Pharmacol. (1992) 227: 6370.
  • WEBB ML, LIU EC, COHEN RB, HEDBERG A, BOGOSIANEA, MONSHIZADEGAN H, MOLLOY C, SERAFINO R, MORE-LAND S, MURPHY TJ: Molecular characterization of angiotensin II type II receptors in rat pheochromocy-tosna cells. Peptides (1993) 13: 499–508.
  • SUMNERS C, TANG W, ZELENZA B, RAIZDA MK: Angioten-sinII receptor subtypes are coupled with distinct signal transduction mechanisms in neurons and astrocytes from rat brain. Proc. Nat. Acad. Sci. USA (1991) 88: 7567–7571. The first report of AT2 mediated effect upon intracellular cGMP
  • BOTTARI SP, KING IN, REICHLIN S, DAHLSTROEM I, LY-DON N, DE GASPARO M: The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanykyclase. Bio-chem. Biophys. Res. Commun. (1992) 183: 206211. The first report of AT2 receptor mediation of PTP activity.
  • BRECHLER V, JONES PW, LEVENS NR, DE GASPARO M, BOTTARI SP: Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. Regul. Pep. (1993) 44: 207213. Defines CGP42112A as an AT2 agonist and PD 123319 as an AT2 antagonist.
  • GUIFFO GM, HEEMSHERK FMJ, SAAVEDRA JM: Purifica-tion and characterization of angiotensin 11 AT2 recep-tors from neonatal rat kidney. Proc. Nat. Acad. Sci. USA (1993) 90: 110091103. A recent report detailing solubilisation of the AT2 receptor and purification by a two step process of gel filtration, followed by affinity chromatography.
  • SIEMENS IR, YEE DK, REAGAN LP, FLUHARTY SJ: Affinity purification of angiotensin type 2 receptors from N1E115 cells: evidence for agonist-induced formation of multimeric complexes. J. Neurochem. (1994) 62: 257–264. A recent report detailing the solubilisation and affinity purification of the AT2 receptor.
  • REAGAN LP, THEVENIAU M, YANG YD, SIEMENS IR, YEE DK, REISINE T, FLUHARTY SJ: Development of poly-clonal antibodies against the angiotensin type 2 recep-tors. Proc. Natl. Acad. Sci. USA (1993) 90: 7596–7960.
  • SIEMENS IR, ADLER HJ, ADDYA K, MAH SJ SJF: Biochemi-cal analysis of solubRized angiotensin II receptors from murine neuroblastoma N1E115 cells by covalent crosslinking and affinity purification. Mol. Pharmacol. (1991) 40: 717–726.
  • SIEMENS IR, SWANSON GN, FLUHARTY SJ, HARDING JW:Solubilization and partial characterization of angioten-sin II receptors from rat brain. J. Neurochem. (1991) 57: 690–700.
  • PUCELL AG, HODGES JC, SEN I, RUMPUS FM, HUSAIN A:Biochemical properties of the ovarian granulosa cell type 2 angiotensin 11 receptor. Endocrinol. (1991) 128: 1947–1949.
  • DUDLEY DT, HUBBELL SE, SUMMERFELT EM: Charac-terization of angiotensin U (AT2) binding sites in R3T3 cells. Mol. Pharmacol. (1991) 40: 360367.
  • PRATT RE, WANG D, HEIN L, DZAU VJ: The AT2 isoformof the angiotensin receptor mediates myointimal hy-perplasia following vascular injury. Hypertension (1992) 20: 432.21.
  • JANIAK P, PILLON A, PROST JF, VILAINE JP: Role ofangiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension (1993) 20: 737–745.
  • VISWANATHAN M, SAAVEDRA JM: Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing. Peptides (1992) 13.
  • VISWANATHAN M, C. S, SELTZER A, SAAVEDRA JM: Bal-loon angioplasty enhances the expression of angioten-sin II receptors in rat aorta. J. Clin. Invest. (1992) 90: 1707–1712.
  • KAMBAYASHI Y, BARDHAN S, INAGAMI T: Peptkle growth factors markedly decrease the ligand binding of angiotensin II type 2 receptor in rat cultured vascular smooth muscle cells. Biochern. Biophys. Res. Commun. (1993) 194: 478–482.
  • BUNKENBURG B, VAN AMELSVOORT T, ROGG H, WOOD J: Receptor-mediated effect of angiotensin lion growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension (1992) 20: 746–754.
  • WONG PC, CHRIST DD, TIMMERMANS PBMWM: Enhance-ment of losartan (DuP 753) induced angiotensin II receptor antagonism by PD 123177 in rats. Eur. J. Phar-macol. (1992) 220: 267–270.
  • WIDDOP RE, GARDINER SM, KEMP PA, BENNETT T: Inhi-bition of the haemodynamic effects of angiotensin II in conscious rats by AT2 receptor antagonists given after the AT' antagonist, IDIP 3174. Br. J. Pharmacol. (1992) 107: 873–880.
  • SCHEUER DA, PERRONE MH: Angiotensin type 2 recep-tors mediate depressor phase of biphasic pressure response to angiotensin. Am.J. Physiot (1993) 264: R917–R923.
  • MARCHANT C, BROWN L, SERNIA C: Renin-angiotensinsystem in thyroid dysfunction in rats. J. Cardiovasc. Pharmacol. (1993) 22: 449–455.
  • MATSUBARA L, BRLLLA CG, WEBER KT: Angiotensin II-mediated inhibition of collagenase activity in cul-tured cardiac fibroblasts. FASEB (1992) 6: A941.
  • BRILLA CG: Angiotensin II type 2 receptor-mediatedstimulation of collagen synthesis in human cardiac fibroblasts. Circulation (1992) 86: 189.
  • WIEMER G, SCHOLKENS BA, BUSSE R, WAGNER A, HEITSCH H, LINZ W: The functional role of angiotensin 11 subtype AT2 receptors in endothelial cells and iso-lated ischemk rat hearts. Pharm. Pharmacol. Len. (1993) 3: 2427.
  • ICEISER JA, BJORK FA, HODGES JC, TAYLOR DG: Renalhemodynamic and excretory responses to PD 123319 and losartan, nonpeptide ATi and AT2 subtype-specific angiotensin U ligands. J. Pharrn. Exp. Ther. (1992) 262: 11541160.
  • MACARI D, BOTTARI S, WHITEBREAD S, DE GASPARO M,LEVENS N: Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in sodium-depleted rat. Eur.J. Pharmacol. (1993) 249: 85–93.
  • GOLDFARB DA, DIZ DI, TUBBS RR, FERRARI° CM, NOVICKAC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J. Urol. (1994) 151: 208–213.
  • COGAN MG, LID FY, WONG PC, TIMMERMANS PBMWM: Comparison of inhibitory potency by nonpeptide angiotensin II receptor antagonists PD 123177 and DuP 753 on proximal nephron and renal transport. J. Pharrn. E. Ther. (1991) 259.
  • KANG J, SUMNERS C, POSNER P: Modulation of net outward current in cultured neurons by angiotensin involvement of AT' and AT2 receptors. Brain Res. (1992) 580: 317324.
  • BUISSON B, BOTTARI SP, DE GASPARO M, GALLOPAYET N, PAYET MD: The angiotensin AT2 receptor modulates T-type calcium current in nondifferentiated NG10815 cells. FEBS Lett. (1992) 309: 161–164.
  • AMBÜHL P, FELIX D, IMBODEN H, KHOSLA MC, FERRARI° CM: Effects of angiotensin II and its selective antago-nists on inferior olivary neurones. Reg. Peptides (1992) 41: 19–26.
  • AMBOHL P, IMBODEN H, FELIX D: Wirkung von angiotensinrezeptorantagonisten auf nervenre-ilen des zentralnervensystems. Nieren Hochdruck (1993) 22: 287–291.
  • KANG J, SUMNERS C, POSNER P: Angiotensin II type 2 receptor-modulated changes in potassium currents. Am. J. Physio 1(1993) 265: C607–C616.
  • BARNES NM, COSTALL B, KELLY ME, MURPHY DA, NAY-LOR RJ: Cognitive enhancing actions of PD 123177 detected in a mouse habituation paradigm. NeuroReport (1991) 2: 351–353.
  • TONEY GM, PORTER JP: Functional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response. Brain Res. (1993) 603: 57–63.
  • WIDDOP RE, GARDINER SM, KEMP PA, BENNETT T: Cen-tral administration of PD 123319 or EXP3174 inhibits effects of angiotensin U. Am. J. Physiol. (1993) 264: H117–H125.
  • WIDDOP RE, GARDINER SM, KEMP PA, BENNETT T: Dif-ferential blockade of central effects of angiotensin II by AT2receptor antagonists. Am.J. Physiol. (1993) 265: H226–H231.
  • HOGARTY DC, SPEAKMAN EA, PUIG V, PHILLIPS MI: The role of angiotensin, ATI and AT2 receptors in the pres-sor, drinking and vasopressin responses to central angiotensin. Brain Res. (1992) 586: 289–294.
  • STROMBERG C, NAVERI L, SAAVEDRA J: Angiotensin AT2 receptors regulate cerebral blood flow in rats. NeuroRe-port (1992) 3: 703–704.
  • NAVERI L, STROMBERG C, SAAVEDRA JM: Angiotensin AT2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319.1 Cervb. Blood. Flow Metab. (1994) 14: 38–44.
  • STROMBERG C, NAVERI L, SAAVEDRA JM: Nonpeptide angiotensin ATI and AT2 receptor ligands modulate the upper limit of cerebral blood flow autoregulation in rats. J. Cereb. Blood Flow Metab. (1993) 13: 298–303.
  • BRIX J, HABERL RI: The AT2receptor mediates endothe-lium-dependent dilation of rat brain arterioles. FASEJ3J. (1992) 6: A1264.
  • WERNER C, KOCHS E, RABITO S, STORENBURG HJ, SCHULTE AM ESCH J: The effects of angiotensin-II re-ceptor antagonists on neurologic outcome following Incomplete ischemia in rats. Anesthesiology (1993) 79: A740.
  • SCHIAVONE MT, BROSNIHAN KB, KHOSLA MC, FERRARIOCM: Angiotensin II activation of Vasopressin release in the rat hypothalamo-neurohypophysial system is me-diated by the type 2 angiotensin receptor. Hypertension (1991) 17: 425.
  • STEPHENSON KN, STEELE MK: Brain angiotensin II re-ceptor subtypes and the control of luteinizing hormone and prolactin secretion in female rats. J. Neuroendocri-not (1992) 4: 441–447.
  • JAISWAL N, TALLANT EA, KHOSLA MC, FERRARI° CM: Subtype 2 angiotensin receptors mediate prostaglandin synthesis in human astrocytes. Hypertension (1991) 17: 1115–1120.
  • ROWLAND NE, FREGLY M.J: Brain angiotensin AT2 recep-tor antagonism and water intake. Brain Res. Bull. (1993) 32: 391–394.
  • DOURISH CT, DUGGAN JA, GANKS RJA: Drinking in-duced by subcutaneous injection of angiotensin II in the rat is blocked by the selective ATI antagonist DuP 753 but not by the selective AT2 antagonist WL19. Eur. J. Pharmacol. (1992) 211: 113–116.
  • WONG PC, HART SD, ZASPEL A, CHIU AT, SMITH RD, TIMMERMANS PBMWM: Functional studies of nonpep-tide angiotensin II receptor subtypespecific Ligands: DuP 753 (Am) and PD123177 (A112). J. Pbarm. Exp. Ther. (1990) 255: 584–592.
  • CHEN LI, PRAKASH OM, RE RN: The interaction of insulinand angiotensin II on the regulation of human neuroblastoma cell growth. Mol. Chem. Neuropathol. (1993) 18: 189–196.
  • BRYSON SE, WARBURTON P, WINTERSGLLL HP, DREW GM, MICHEL AD, BALL SG, BALMFORTH AJ: Induction of the angiotensin AT2 receptor subtype expression by differ-entiation of the neuroblastoma X glioma hybrid, NG10815. Eur. J. Pharmacol. (1993) 225: 119–127.
  • TALLANT EA, DIZ DI, KHOSLA MC, FERRARI° CM: Iden-tification and regulation of angiotensin II receptor subtypes on NG10815 cells. Hypertension (1991) 17: 1135–1143.
  • KIMURA B, SUMNERS C, PHILLIPS MI: Changes in skin angiotensin ll receptors in rats during wound healing. Biochem. Biophys. Res. Commun. (1992) 187: 1083–1090.
  • BRUNSWIGSPICKENHEIER B, MUKHOPADHYAY K: Char-acterization of angiotensin II receptor subtype on bo-vine thecal cells and its regulation by luteinizing hormone. Endocrinol. (1992) 131.
  • ANDRADEGORDON P, ZRECK T, APA R, NAFTOLIN F: Roleof angiotensin II in the processes leading to ovulation. Biochem. Pharmacol. (1991) 42: 715719.
  • LE GALL S, FERAL C, LEYMARIE P: Système ren-ine/angiotensine de l'uterus et de Fovaire chez lea femelles de mammireres. Reprod. Nutr. Dev. (1993) 33: 185–198.
  • YOSHIMLTRA Y, KARUBE M, KOYAMA N, SHIOKAWA S, NANNO T, NAKAMURA Y: Angiotensin II directly in-duces follicle rupture and oocyte maturation in the rabbit. FEBS Lett (1992) 307: 305–308.
  • AIYAR N, GRIFFIN E, EDWARDS R, WEINSTOCK J, SAMA-NEN J, NAMBI P: Characterization of bovine ovary angiotensin II receptors using subtypeselective antago-nists. Pharmacol. (1993) 46: 18.
  • PETERSON CM, ZHU C, MUKAIDA T, BUTLER TA, WOESS-NER JR. JF, LEMAIRE WJ: The angiotensin II antagonist saralasin inhibits ovulation in the perfused rat ovary. Am. J. Obstet. Gynecol. (1993).
  • COX BE, IPSON MA, SHAUL PW, KAMM KR, ROSENFELD CR: Myometrial angiotensin II receptor subtypes change during ovine pregnancy. J. Ctn. Invest. (1993) 92: 2240–2248.
  • GRADY EF, KALINYAK JE: Expression of AT2 receptorsin rat foetal subdermal cells. Reg. Peptides (1993) 44: 171–180.
  • GRADY EF, SECHI LA, GRIFFIN CA, SCHAMBELAN M, KALINYAK JE: Expression of AT2 receptors in the devel-oping rat fetus. J. Clin. Invest. (1991)88: 921–933.
  • SECHI LA, GRIFFIN CA, GRADY EF, KALINYAK JE: Char-acterization of angiotensin II receptor subtypes in rat heart. Circ. Res. (1992) 71: 1482–1489.
  • ZEMEL S, MILLAN MA, FEUILLAN P, AGUILERA G: Charac-terization and distribution of angiotensin-II receptors in the primate fetus. J. Clin. Endocrinol. Metab. (1991) 71.
  • TSUTSUMI K, STROMBERG C, VISWANATHAN M, SAAVE- DRA JM: Angiotensin-II receptor subtypes in foetal tissues of the rat: autoradiography, guankte nucleotide sensitivity and association with phosphoinositide hy-drolysis. Endocrinol. (1991) 129: 1075–1082.
  • VISWANATHAN M, TSUTSUMI K, CORREA FMA, SAAVEDRA JM: Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem. Biophys. Res. Commun. (1991) 179: 1361–1367.
  • MILIAN MA, JACOBOWITZ DM, AGUILERA G, CATT KJ: Differential distribution of ATI and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc. Natl. Acad. Sci. USA (1991) 88: 11440–11444.
  • FEUILLAN PP, MILLAN MA, AGUILERA G: Angiotensin binding sites in the rat fetus: characterization of recep-tor subtypes and interaction with guanyl nucleotides. Reg. Pept. (1993) 44: 159–169.
  • LEVENS NR, DE GASPARO M, WOOD JM, BOTTARi SP: Could the pharmacological differences observed be-tween angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharmacol. Toxicol (1992) 71: 241–249.
  • ZHANG J, ENTZEROTH M, WIENEN W, VAN MEEL JCA:
  • •Characterization of BIBS-39 and BIBS-222: Two new nonpeptide angiotensin ll receptor antagonists. Fur. J. Pharmacol. (1992) 218: 35–41. The first report of nonpeptide balanced ATI/AT2 antagonists. De-scribes angiotensin blocking activity of BIBS-39 and BIBS-222 in vitro and following iv administration in vivo.
  • DE LAZLO SE, QUAGLIATO CS, GREENLEE 'WJ, PATCHETT
  • •AA, CHANG RSL, LOTTI VJ, Cl-LEN TB, SCHECK SA, FAUST KA, KIVLIGHN SD, SCHORN TS, ZINGARO GJ, SIEGL PKS: A potent, orally active, balanced affinity angiotensin ATI antagonist and AT2 binding inhibitor. J. Med.Chem. (1993) 36: 3207–3210. Describes L159,689 and related analogues as balanced ATI/AT2 antagonists.
  • GOLDBERG MR, TANAKA W, BARCHOWSKY A, BRAD-STREET it, MCCREA J, LO MW, MCWILLIAMS EJ, BJORNS-SON TD: Effects of Losartan on blood pressure, plasma91. renin activity, and angiotensin Il in volunteers. Hyper-tension (1993) 21: 704–713.
  • BLANKLEY CJ, HODGES JC, KLUTCHKO SR, HIMMELSBACH RJ, CHUCHOLOWSKI A, CONNOLLY CJ, NEERGAARD SJ,VAN NIEUWENHZE MS, SEBASTIAN A, QUIN J: Synthesis and structure-activity relationships of a novel series of nonpeptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem. (1991) 34: 3248–3260. Describes structure-activity relationships for PD 123319 and ana-logues.
  • WV MT, LICELER TJ, ASHTON WT, CHANG RSL, LOTTI VJ,GREENLEE WJ: Synthesis and structure-activity relation-ships of a novel series of nonpeptide AT2 selective angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett. (1993) 3: 2023–2028. Describes L159686, including oral bioavailability and pharmacoki-netic data indicating its usefulness as an in vivo research tool.
  • KLUTCHKO S, HAMBY JM, HODGES JC: Tetrahydroiso-,.quinoline derivatives with AT2-spedfic angiotensinreceptor binding inhibitory activity. BiooT. Med. Chem. Lett. (1994) 4: 57–62. Provides an in vitro comparison of PD 123319, L159686 and PD 126055 under identical conditions.
  • VANATTEN MK, ENSINGER CL, CHIU AT, MCCALL DE,NGUYEN TT, WEXLER RR, TIMMERMANS PBMWM: A novel series of selective nonpeptide inhibitors of angiotensin U binding to the AT2 site. J. Med. Chem. (1993) 36: 3985–3992. Describes EXP801 and analogues as AT2 specific antagonists.
  • GLINKA TW, DE LAZLO SE, TRAN J, CHANG RS, CHEN T-B,•• LOUT VJ, GREENLEE WJ: L-161,638: a potent AT2 selec-tive quinazolinone angiotensin II binding inhibitor. Bioorg. Med. Chem. Lett. (1994) 4: 1479–1484. Describes the spectrum of angiotensin receptor selectivity for qui-nazolinone derivatives that range from AT: selective to balanced AT1/AT2 to AT2 selective agents such as L-161,638.
  • GLINKA TW, DE LAZLO SE, SIEGL PM, CHANG RS,KIVLIGHN SD, SCHORN TS, FAUST KA, CHEN TB, ZINGARO GJ, LOUT VJ, GREENLEE WJ: A new class of balanced AT1/AT2 angiotensin 111 antagonists: quinazoline anntagonists with acylsulfonamide and sulfonylcar-bamate acidic functionalities. Bioorg. Med. Chem. Lett. (1994) 4: 81–86. Describes analogues of L162,393 as balanced ATIJAT2 antagonists.
  • MANTLO NB, KIM D, ONKEYKA D, CHANG RSL, KIVLIGHNSD, SIEGL PKS, GREENLEE WJ: Potent imidazo[4,5b]pyri-dine angiotensin II antagonists which exhibit balanced affinity to the AT: and AT2 receptor subtypes. Btoorg. Med. Chem. Lett. (1994) 4: 17–22. Describes L162,441 and L162,620, two compounds with subnano-molar IC5o values for both AT: and AT receptors and oral ED5o values less than 1 mg/kg in rats.
  • CHAKRAVARTY PK, STRELITZ RA, CHEN TB, CHANG RSL,LOUT VJ, ZINGARO GJ, SCHORN TW, KIVLIGHN SD, SIEGL PKS, PATCHETT AA, GREENLEE WJ: Quinazolinone biphenyl acylsulfonamides: a potent new class of angiotensin-II receptor antagonists. Bioorg. Med. Chem. Lett. (1994) 4: 75–80.
  • KIM D, MANTLO NB, ONDEYKA D, CHANG RSL, KIVLIGHNSD, SIEGL PKS, GREENLEE WJ: Potent bnidazopyridine angiotensin II antagonists with balanced affinity to ATi and AT2 receptor subtypes. Abstr 207th Am .Chem. Soc. Meet. (1994) MEDI: #208.
  • KEVIN NJ, RIVER° RA, GREENLEE WJ, CHANG RSL, CHENTB: Substituted phenylthiophene benzoylsul-fonamides with potent binding affinity to angiotensin II AT: and AT2 receptors. Bioorg. Med. Chem. Lett. (1994) 4: 189–194. Describes L162,065 (compound Ie), a balanced AT1/AT2 antagonist with weaker in vitro potency than other compounds reported by Merck.
  • FLANAGAN RE, CHANG LL, ASHTON WT, CHAKRAVARTYPK, PATCHETT AA, GREENLEE WJ, CHANG RSL, LOUT VJ, KIVLIGHN SD, SIEGL PKS: Potent and orally active tria-zolone All antagonists. Part I: substitutedaryl and cy-cloalkyl acylsulfonamides; sulfonylcarbamates. Abstr 206th Am. Chem. Soc. Meet. (1993) MEDI: #80.
  • HUTCHINS SM, ASHTON WT, CHANG LL, FLANAGAN RE, CHAKRAVARTY PK, GREENLEE WJ, CHANG RSL, LOUT VJ, KIVLIGHN SD, SIEGL PKS: Potent and orally active tria-zolone angiotensin II antagonists. Part IL heterocyclic and related acylsulfonamides. Abstr 206th Am Chem Soc Meet (1993) MEDI: #81.

References to Patent Literature

  • OLSON RE, LIU J, LALKA GK, DUNCIA JV, WEXLER RR, CHIU • AT, MCCALL DE, WONG P, TIMMERMANS PBMWM: Non-peptide angiotensin II antagonists with affinity for ATi and AT2 receptors. Abstr 206th Am .Chem. Soc. Meet. (1993) MEDI: #77. Describes structure-activity relationships leading to the balanced AT1AT2 antagonist, XH148.
  • SANTELLA III JB, ENSINGER CL, VANATTEN MK, CARINI DJ, • WEXLER RR, CHIU AT, MCCALL DE, WONG PC, TIMMER-MANS PBMWM, DUNCIA JV: Angiotensin la antagonists which exhibit binding affinities for both the AT: and AT2 receptor subtypes. Abstr 207th Am. Chem. Soc. Meet. (1994) MEDI: #199. Describes structure-activity relationships leading to balanced AT1AT2 antagonists.
  • QUAN ML, OLSON RE, CARINI DJ, ELLIS CD, LALICA GK, LIUJ, VANATTEN MK, WEXLER RR, CHIU AT, WONG PC,TIMMERMANS PBMWM: Balanced AT1/AT2 angiotensin II receptor antagonists. Abstr 207th Am. Chem. Soc. Meet. (1994) MEDI: #201. Describes structure-activity relationships of EXP597 analogues as balanced AT1AT2 anatagonits. These authors have also submited a paper to Bioorg. Med. Lett. entitled "Balanced angiotensin II receptor antagonists. I. The effects of biphenyl Ortho'-substitution on affini-ties ATIAT2".
  • ROGG H, SCHMID A, DE GASPARO M: Identification and characterization of angiotensin II receptor subtypes in rabbit ventricular myocardium. Biochem. Biophys. Res. Commun. (1990) 173: 416–422.
  • WONG PC, DUNCIA JV, SANTELLA JB, SMITH RD, WEXLER RR, TIMMERMANS PBMWM, CHIU AT: E7CP597, a nonpep-tide angiotensin II receptor antagonist with high affini-ties for the angiotensin AT: and AT2 receptor subtypes. Eur. J. Pharmacol. (1994) 260: 261–264.
  • QUAN ML, DELUCCA I, BOSWELL GA, CHIU AT, WONG PC, WEXLER RR, TIMMERMANS PBMWM: Imidazolinones as nonpeptide angiotensin U receptor antagonists. Bioorg. Med. Chem. Len. (1994) 4: 1527–1530.
  • ASHTON wT, CHANG LL, FLANAGAN ICI., HUTCHINS SM, NAYLOR EM, CHAKRAVARTY PK, PATCHETT AA, GREEN-LEE WJ, CHEN T-B, FAUST KA, CHANG RSL, LOUT VJ, SINGARO GJ, SCHORN TW, SIEGL PKS, KIVLIGHN SD: Triazolinone biphenylsuffonamide derivatives as orally active angiotensin II antagonists with poten AT1
  • WARNER-LAMBERT COMPANY, EP-24 5637-A (1988).
  • WARNER-LAMBERT COMPANY, W09315734 (1993).
  • WARNER-LAMBERT COMPANY, US5246943 (1993).
  • WARNER-LAMBERT COMPANY, W09205784 (1992).
  • MERCK & COMPANY INC, W09229661 (1992).
  • El DUPONT DE NEMOURS & COMPANY, US5236934 (1993).
  • El DUPONT DE NEMOURS & COMPANY, US5091390 (1992).
  • WARNER-LAMBERT COMPANY, US4812462 (1989) (The is-sued US patent corresponding to EP–245637–A).
  • DR KARL THOMAE GmbH, EP-392317-A (1990).
  • DR KARL THOMAE GmbH, DE4031635-A (1992).
  • MERCK & COMPANY INC, EP-411766-A (1991).
  • MERCK & COMPANY INC, EP-503838-A (1992).
  • MERCK & COMPANY INC, EP-512870-A (1992).
  • MERCK & COMPANY INC, EP-513979-A (1992).
  • MERCK & COMPANY INC, W09323399 (1993).
  • MERCK & COMPANY INC, W09402142 (1994).
  • MERCK & COMPANY INC, GB2269818-A (1994).
  • MERCK & COMPANY INC, W09220662 (1992).
  • El DUPONT DE NEMOURS & COMPANY, US5219856 (1993).
  • MERCK & COMPANY INC, US5252574 (1993).
  • MERCK & COMPANY INC, US5262412 (1993).
  • KUREHA KAGAKU KOGYO KABUSHIKI KAISHA, EP-589665-A (1994).
  • CIBA-GEIGY AG, W09413651 (1994).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.